Return to homepagePandemic Pact

Bundibugyo Ebolavirus Vaccine Candidate Using rVSV Platform

  • Funded by Coalition for Epidemic Preparedness Innovations (CEPI)
  • Total publications:0 publications

Grant number: PRJ-9796

Grant search

Key facts

  • Disease

    Ebola

  • Start & end year

    2026
    2026

  • Known Financial Commitments (USD)

    $3,200,000

  • Funder

    Coalition for Epidemic Preparedness Innovations (CEPI)

  • Research Location

    Congo (DRC), Uganda

  • Lead Research Institution

    International Aids Vaccine Institute

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    N/A

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

CEPI committed initial funding of up to US$3.2 million to IAVI to generate a Master Virus Seed stock and initiate testing using material originally developed at The University of Texas Medical Branch. The candidate uses the rVSV vaccine platform that forms the basis of an approved WHO-prequalified vaccine against Zaire ebolavirus. The programme aims to rapidly advance development of a Bundibugyo ebolavirus vaccine candidate towards clinical evaluation during the ongoing outbreak in the Democratic Republic of the Congo and Uganda.